Literature DB >> 11081389

Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.

S Tanikawa1, S Mori, K Ohhashi, H Akiyama, T Sasaki, H Kaku, K Hiruma, T Matsunaga, T Morita, H Sakamaki.   

Abstract

Hepatic veno-occlusive disease (VOD) is a major complication after hematopoietic stem cell transplantation (HSCT). Aetiological determinants, diagnosis and treatment remain unclear. Changes in coagulation-fibrinolysis parameters and N-terminal propeptide for type III procollagen (P-III-P) have been studied in patients with or without VOD after HSCT. We prospectively measured protein C activity, tissue plasminogen activator (t-PA), antithrombin III (AT-III), plasminogen activity (PLG), thrombin-antithrombin III (TAT), alpha2-plasmin inhibitor (alpha2-PI),fibrinogen (Fbg) and P-III-P in 44 consecutive adult patients undergoing allogeneic HSCT. Each parameter was determined before conditioning, on day 0 of HSCT and weekly for 5 weeks. Five of the 44 patients developed VOD at a median post HSCT of day 3 (range, day 3 to 12). On repeated analysis of variance (ANOVA), there were significant differences between patients with and without VOD in P-III-P (P < 0.0001), protein C (P < 0.0001), t-PA (P < 0.0001), PLG (P < 0.0001), AT-III(P < 0.0001), Fbg (P < 0.0001), alpha2-PI (P = 0.0002). Levels of P-III-P were significantly higher in patients with VOD than without VOD, before preparative chemotherapy (P < 0.005) and on days 0 and 7 (P < 0.001). On day 0, levels of t-PA were significantly higher in patients with VOD than without VOD (P < 0.05). On day 7, levels of protein C were significantly lower in patients with VOD than without VOD (P < 0.01). On day 0, there were trends of differences (P = 0.0515) between patients with and without VOD in the levels of protein C. These results suggest P-III-P, t-PA and protein C are predictive markers for VOD after HSCT in adults. Moreover, the serum P-III-P level before start of conditioning might indicate patients at risk for developing VOD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081389     DOI: 10.1038/sj.bmt.1702624

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Prediction of veno-occlusive disease using biomarkers of endothelial injury.

Authors:  Corey Cutler; Haesook T Kim; Shaké Ayanian; Gary Bradwin; Carolyn Revta; Julie Aldridge; Vincent Ho; Edwin Alyea; John Koreth; Philippe Armand; Robert Soiffer; Jerome Ritz; Paul G Richardson; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-23       Impact factor: 5.742

2.  Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin.

Authors:  Joohyun Ryu; Se Ryeon Lee; Sung Goo Park; Sunghyun Kang; Hyeoung-Joon Kim; Byoung Chul Park
Journal:  Exp Mol Med       Date:  2010-09-30       Impact factor: 8.718

3.  Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Authors:  Paul G Richardson; Robert J Soiffer; Joseph H Antin; Hajime Uno; Zhezhen Jin; Joanne Kurtzberg; Paul L Martin; Gideon Steinbach; Karen F Murray; Georgia B Vogelsang; Allen R Chen; Amrita Krishnan; Nancy A Kernan; David E Avigan; Thomas R Spitzer; Howard M Shulman; Donald N Di Salvo; Carolyn Revta; Diane Warren; Parisa Momtaz; Gary Bradwin; L J Wei; Massimo Iacobelli; George B McDonald; Eva C Guinan
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-16       Impact factor: 5.742

4.  Veno occlusive disease: update on clinical management.

Authors:  M Senzolo; G Germani; E Cholongitas; P Burra; A-K Burroughs
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

5.  Expression of MMP-9 in hepatic sinusoidal obstruction syndrome induced by Gynura segetum.

Authors:  Xia-zhen Yu; Tao Ji; Xue-li Bai; Liang Liang; Lin-yan Wang; Wei Chen; Ting-bo Liang
Journal:  J Zhejiang Univ Sci B       Date:  2013-01       Impact factor: 3.066

6.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

Authors:  S Corbacioglu; E Carreras; M Ansari; A Balduzzi; S Cesaro; J-H Dalle; F Dignan; B Gibson; T Guengoer; B Gruhn; A Lankester; F Locatelli; A Pagliuca; C Peters; P G Richardson; A S Schulz; P Sedlacek; J Stein; K-W Sykora; J Toporski; E Trigoso; K Vetteranta; J Wachowiak; E Wallhult; R Wynn; I Yaniv; A Yesilipek; M Mohty; P Bader
Journal:  Bone Marrow Transplant       Date:  2017-07-31       Impact factor: 5.483

7.  Evaluation of thromboelastometry parameters as predictive markers for sinusoidal obstruction syndrome in patients undergoing allogeneic stem cell transplantation for acute leukaemia.

Authors:  Joanna Rupa-Matysek; Lidia Gil; Ewelina Wojtasińska; Zuzanna Kanduła; Adam Nowicki; Magdalena Matuszak; Mieczysław Komarnicki
Journal:  Oncotarget       Date:  2017-06-15

8.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; F Dignan; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; S Okamoto; A Pagliuca; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; R F Duarte; E Carreras
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483

9.  Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.

Authors:  Sihe Jiang; Olaf Penack; Tobias Terzer; David Schult; Joshua Majer-Lauterbach; Aleksandar Radujkovic; Igor W Blau; Lars Bullinger; Carsten Müller-Tidow; Peter Dreger; Thomas Luft
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.